Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Levofloxacin | hsa00120 | Primary bile acid biosynthesis | 3.72E-02 | 2 | P22680, P22307 | CYP7A1, SCP2 | More | | Levofloxacin | hsa00340 | Histidine metabolism | 4.52E-02 | 1 | O95954 | FTCD | More | | Levofloxacin | hsa00564 | Glycerophospholipid metabolism | 9.70E-03 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | | Levofloxacin | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Levofloxacin | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Levofloxacin | hsa00630 | Glyoxylate and dicarboxylate metabolism | 6.94E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Levofloxacin | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Levofloxacin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Levofloxacin | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Levofloxacin | hsa01100 | Metabolic pathways | 2.25E-02 | 7 | Q9Y259, Q13956, P49619, O95954, Q02318, Q9UBX8, P35573 | CHKB, PDE6H, DGKG, FTCD, CYP27A1, B4GALT6, AGL | More | | Levofloxacin | hsa01524 | Platinum drug resistance | 4.67E-02 | 4 | Q13489, P98170, P78417, P43246 | BIRC3, BIRC4, GSTO1, MSH2 | More | | Levofloxacin | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | | Levofloxacin | hsa03013 | RNA transport | 4.09E-02 | 9 | P52298, Q09161, O14893, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | | Levofloxacin | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | | Levofloxacin | hsa03040 | Spliceosome | 4.87E-03 | 7 | O43143, P08579, P26368, Q13595, Q07955, P84103, Q13243 | DHX15, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS3, SFRS5 | More | | Levofloxacin | hsa03320 | PPAR signaling pathway | 1.62E-02 | 2 | Q13133, Q02318 | NR1H3, CYP27A1 | More | | Levofloxacin | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Levofloxacin | hsa04062 | Chemokine signaling pathway | 3.81E-02 | 6 | P07948, P62873, P63218, P50151, P43250, Q13009 | LYN, GNB1, GNG5, GNG10, GRK6, TIAM1 | More | | Levofloxacin | hsa04064 | NF-kappa B signaling pathway | 1.91E-04 | 12 | P10415, Q13489, P25963, P51617, O00463, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q13315, P24522 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, ATM, GADD45A | More | | Levofloxacin | hsa04071 | Sphingolipid signaling pathway | 9.39E-03 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Levofloxacin | hsa04080 | Neuroactive ligand-receptor interaction | 1.18E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21462, P21730 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1 | More | | Levofloxacin | hsa04110 | Cell cycle | 3.57E-02 | 3 | Q9UBD5, P06493, P33981 | ORC3, CDK1, TTK | More | | Levofloxacin | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Levofloxacin | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | | Levofloxacin | hsa04145 | Phagosome | 1.98E-02 | 8 | Q15080, P14598, Q13509, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Levofloxacin | hsa04210 | Apoptosis | 1.52E-02 | 9 | Q13315, P10415, Q13489, P25963, P01375, P24522, Q16548, Q13077, Q14643 | ATM, BCL2, BIRC3, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, ITPR1 | More | | Levofloxacin | hsa04217 | Necroptosis | 3.71E-05 | 11 | P01568, Q13489, P98170, P07900, P08238, P15104, P05141, P01584, P0C0S5, Q13557, P21796 | IFNA21, BIRC3, BIRC4, HSP90AA1, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D, VDAC1 | More | | Levofloxacin | hsa04371 | Apelin signaling pathway | 3.23E-04 | 7 | P62873, P63218, P50151, Q13485, P84022, Q16566, P0DP23 | GNB1, GNG5, GNG10, SMAD4, SMAD3, CAMK4, CALM1 | More | | Levofloxacin | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Levofloxacin | hsa04613 | Neutrophil extracellular trap formation | 1.51E-04 | 17 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, P21730, P21462 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1 | More | | Levofloxacin | hsa04621 | NOD-like receptor signaling pathway | 3.10E-03 | 11 | Q14643, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P12838 | ITPR1, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA4 | More | | Levofloxacin | hsa04657 | IL-17 signaling pathway | 4.87E-02 | 2 | P07900, P01584 | HSP90AA1, IL1B | More | | Levofloxacin | hsa04660 | T cell receptor signaling pathway | 4.20E-02 | 7 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK | More | | Levofloxacin | hsa04668 | TNF signaling pathway | 2.59E-02 | 7 | P01375, O00463, Q13489, P25963, P20749, Q13077, P14780 | TNF, TRAF5, BIRC3, NFKBIA, BCL3, TRAF1, MMP9 | More | | Levofloxacin | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Levofloxacin | hsa04713 | Circadian entrainment | 1.78E-03 | 5 | O15399, P0DP23, P62873, P63218, P50151 | GRIN2D, CALM1, GNB1, GNG5, GNG10 | More | | Levofloxacin | hsa04720 | Long-term potentiation | 2.33E-02 | 3 | Q16566, P0DP23, O15399 | CAMK4, CALM1, GRIN2D | More | | Levofloxacin | hsa04724 | Glutamatergic synapse | 1.11E-03 | 5 | O15399, P62873, P63218, P50151, P15104 | GRIN2D, GNB1, GNG5, GNG10, GLUL | More | | Levofloxacin | hsa04725 | Cholinergic synapse | 9.51E-03 | 4 | P62873, P63218, P50151, Q16566 | GNB1, GNG5, GNG10, CAMK4 | More | | Levofloxacin | hsa04726 | Serotonergic synapse | 2.38E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Levofloxacin | hsa04727 | GABAergic synapse | 2.45E-03 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Levofloxacin | hsa04744 | Phototransduction | 6.94E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Levofloxacin | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Levofloxacin | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | | Levofloxacin | hsa04970 | Salivary secretion | 4.49E-02 | 4 | P22694, Q14643, P17252, P49913 | PRKACB, ITPR1, PRKCA, CAMP | More | | Levofloxacin | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | | Levofloxacin | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | | Levofloxacin | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | | Levofloxacin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | | Levofloxacin | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P62873, P63218, P50151, P43250 | GNB1, GNG5, GNG10, GRK6 | More | | Levofloxacin | hsa05034 | Alcoholism | 4.45E-05 | 11 | O15399, Q16566, P0DP23, P62873, P63218, P50151, Q93077, P62807, Q93079, O60814, P68431 | GRIN2D, CAMK4, CALM1, GNB1, GNG5, GNG10, HIST1H2AC, HIST1H2BC, H2BC9, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Levofloxacin | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Levofloxacin | hsa05132 | Salmonella infection | 2.98E-02 | 11 | P51617, P25963, P01375, Q9UJU2, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, Q13509 | IRAK1, NFKBIA, TNF, LEF1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, TUBB3 | More | | Levofloxacin | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | | Levofloxacin | hsa05140 | Leishmaniasis | 1.18E-02 | 7 | P14598, P13765, O60603, P25963, P01375, P51617, Q15080 | NCF1, HLA-DOB, TLR2, NFKBIA, TNF, IRAK1, NCF4 | More | | Levofloxacin | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Levofloxacin | hsa05152 | Tuberculosis | 2.07E-02 | 9 | Q13488, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Levofloxacin | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Levofloxacin | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | | Levofloxacin | hsa05163 | Human cytomegalovirus infection | 2.00E-02 | 6 | P62873, P63218, P50151, P0DP23, P30101, P01568 | GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21 | More | | Levofloxacin | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.00E-02 | 6 | P01568, P62873, P63218, P50151, P07948, P0DP23 | IFNA21, GNB1, GNG5, GNG10, LYN, CALM1 | More | | Levofloxacin | hsa05168 | Herpes simplex virus 1 infection | 4.43E-02 | 8 | P01568, Q07955, P84103, Q13243, Q13489, P30101, Q13398, Q9NZL3 | IFNA21, SFRS1, SFRS3, SFRS5, BIRC3, PDIA3, ZNF211, ZNF224 | More | | Levofloxacin | hsa05170 | Human immunodeficiency virus 1 infection | 7.15E-05 | 20 | P62873, P63218, P50151, P0DP23, P01375, P17252, O00463, P30101, Q14643, P01568, P51617, P25963, O60603, Q13315, O95067, P23528, P10415, Q13619, Q93034, Q9Y6Q5 | GNB1, GNG5, GNG10, CALM1, TNF, PRKCA, TRAF5, PDIA3, ITPR1, IFNA21, IRAK1, NFKBIA, TLR2, ATM, CCNB2, CFL1, BCL2, CUL4A, CUL5, AP1M2 | More | | Levofloxacin | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | | Levofloxacin | hsa05200 | Pathways in cancer | 3.99E-04 | 15 | Q13751, P08238, P43246, P84022, Q13485, Q13489, P98170, P62873, P63218, P50151, P78417, O75293, P0DP23, P01568, P01042 | LAMB3, HSP90AB1, MSH2, SMAD3, SMAD4, BIRC3, BIRC4, GNB1, GNG5, GNG10, GSTO1, GADD45B, CALM1, IFNA21, KNG1 | More | | Levofloxacin | hsa05202 | Transcriptional misregulation in cancer | 1.51E-04 | 14 | Q12778, Q15532, Q13315, P14780, P14923, Q16548, Q13489, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, JUP, BCL2A1, BIRC3, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Levofloxacin | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Levofloxacin | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Levofloxacin | hsa05210 | Colorectal cancer | 4.67E-02 | 4 | P84022, Q13485, P43246, O75293 | SMAD3, SMAD4, MSH2, GADD45B | More | | Levofloxacin | hsa05212 | Pancreatic cancer | 3.28E-02 | 3 | P84022, Q13485, O75293 | SMAD3, SMAD4, GADD45B | More | | Levofloxacin | hsa05214 | Glioma | 3.28E-02 | 3 | P0DP23, Q16566, O75293 | CALM1, CAMK4, GADD45B | More | | Levofloxacin | hsa05222 | Small cell lung cancer | 3.10E-03 | 9 | Q13751, Q13489, P98170, P10415, P25963, Q13077, O00463, P24522, O75293 | LAMB3, BIRC3, BIRC4, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A, GADD45B | More | | Levofloxacin | hsa05231 | Choline metabolism in cancer | 2.00E-02 | 2 | Q9Y259, P49619 | CHKB, DGKG | More | | Levofloxacin | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Levofloxacin | hsa05321 | Inflammatory bowel disease | 1.28E-02 | 5 | O60603, P01375, P13765, Q14765, P23771 | TLR2, TNF, HLA-DOB, STAT4, GATA3 | More | | Levofloxacin | hsa05322 | Systemic lupus erythematosus | 2.09E-04 | 12 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Levofloxacin | hsa05332 | Graft-versus-host disease | 9.30E-03 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Levofloxacin | hsa05415 | Diabetic cardiomyopathy | 2.87E-02 | 4 | P05141, O15239, P13073, Q13557 | SLC25A5, NDUFA1, COX4I1, CAMK2D | More | | |